Sarepta Therapeutics Inc
F:AB3A
Sarepta Therapeutics Inc
F:AB3A
Price:
18.12
EUR
4.14%
Market Closed
Market Cap:
€1.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Sarepta Therapeutics Inc
F:AB3A
|
US |
|
Sibanye Stillwater Ltd
F:47VS
|
ZA |
|
G
|
Global Payments Inc
F:GLO
|
US |
|
C
|
Caseys General Stores Inc
SWB:CS2
|
US |
|
S
|
Standard Chartered PLC
OTC:SCBFY
|
UK |
|
M
|
Manchester United PLC
XMUN:MUF
|
UK |
|
V
|
Vinci SA
DUS:SQU
|
FR |
Wall St Price Targets
AB3A Price Targets Summary
Sarepta Therapeutics Inc
Sarepta Therapeutics Inc
Wall Street analysts forecast AB3A stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for AB3A is 20.72 EUR with a low forecast of 4.63 EUR and a high forecast of 36.57 EUR.
Lowest Forecast
Price Target
4.63
EUR
74% Downside
Average Forecast
Price Target
20.72
EUR
14% Upside
Highest Forecast
Price Target
36.57
EUR
102% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AB3A's stock price target?
Price Target
20.72
EUR
20.72
EUR
According to Wall Street analysts, the average 1-year price target for AB3A is 20.72 EUR with a low forecast of 4.63 EUR and a high forecast of 36.57 EUR.
What is the Revenue forecast for Sarepta Therapeutics Inc?
Projected CAGR
-3%
-3%
Over the last 14 years, the compound annual growth rate for Revenue has been 32%. The projected CAGR for the next 8 years is -3%.
